![Valerie Marshall](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Valerie Marshall
Profile
Valerie Marshall served as a Finance Director at Greig Middleton & Co. Ltd.
and as a Non-Executive Director at NanoBioDesign Ltd.
Former positions of Valerie Marshall
Companies | Position | End |
---|---|---|
NanoBioDesign Ltd.
![]() NanoBioDesign Ltd. Pharmaceuticals: MajorHealth Technology NanoBioDesign is a life science company developing a commercializing a novel approach to CYP P450 testing based upon the patented concept of 'molecular lego'. NBD's electrochemical array technology produces high information content data relating to how a chemical entity interacts with a CYP P450 and also allows complex drug-drug interaction to be studied quickly and cost effectively. NBD was formed in 2001 as a spin out from Imperial College, London and has research and development activities based at Imperial College and also at the University of Turin, Italy. NBD has an experienced management team and board of directors as well as a dedicated group of investors who are committed to delivering its new paradigm in CYP P450 testing to the marketplace. | Director/Board Member | 2012-12-05 |
Greig Middleton & Co. Ltd. | Director of Finance/CFO | - |
Experiences
Positions held
Linked companies
Private companies | 2 |
---|---|
Greig Middleton & Co. Ltd. | Finance |
NanoBioDesign Ltd.
![]() NanoBioDesign Ltd. Pharmaceuticals: MajorHealth Technology NanoBioDesign is a life science company developing a commercializing a novel approach to CYP P450 testing based upon the patented concept of 'molecular lego'. NBD's electrochemical array technology produces high information content data relating to how a chemical entity interacts with a CYP P450 and also allows complex drug-drug interaction to be studied quickly and cost effectively. NBD was formed in 2001 as a spin out from Imperial College, London and has research and development activities based at Imperial College and also at the University of Turin, Italy. NBD has an experienced management team and board of directors as well as a dedicated group of investors who are committed to delivering its new paradigm in CYP P450 testing to the marketplace. | Health Technology |
- Stock Market
- Insiders
- Valerie Marshall